Oxidative damage and response to Bacillus Calmette-Guérin in bladder cancer cells expressing sialyltransferase ST3GAL1
- PMID: 29454317
- PMCID: PMC5816560
- DOI: 10.1186/s12885-018-4107-1
Oxidative damage and response to Bacillus Calmette-Guérin in bladder cancer cells expressing sialyltransferase ST3GAL1
Abstract
Background: Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of non-muscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumor-associated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown.
Methods: The human bladder cancer (BC) cell line HT1376 strongly expressing the T antigen, was retrovirally transduced with the ST3GAL1 cDNA or with an empty vector, yielding the cell lines HT1376sT and HT1376T, that express, respectively, either the sT or the T antigens. Cells were in vitro challenged with BCG. Whole gene expression was studied by microarray technology, cytokine secretion was measured by multiplex immune-beads assay. Human macrophages derived from blood monocytes were challenged with the secretome of BCG-challenged BC cells.
Results: The secretome from BCG-challenged HT1376sT cells induced a stronger macrophage secretion of IL-6, IL-1β, TNFα and IL-10 than that of HT1376T cells. Transcriptomic analysis revealed that ST3GAL1 overexpression and T/sT replacement modulated hundreds of genes. Several genes preserving genomic stability were down-regulated in HT1376sT cells which, as a consequence, displayed increased sensitivity to oxidative damage. After BCG challenge, the transcriptome of HT1376sT cells showed higher susceptibility to BCG modulation than that of HT1376T cells.
Conclusions: High ST3GAL1 expression and T/sT replacement in BCG challenged-BC cancer cells induce a stronger macrophage response and alter the gene expression towards genomic instability, indicating a potential impact on BC biology and patient's response to BCG.
Keywords: Bacillus Calmette-Guérin; Glycosylation; Sialyl T antigen; Sialyltransferase; Thomsen-Friedenreich antigen.
Conflict of interest statement
Ethics approval and consent to participate
This study does not use samples from diseased persons. The blood used for the preparation of monocyte-derived macrophages was from healthy blood donor voluntaries. For this, no study approval was necessary. The only authorization required was that obtained from the Blood Collection Service of the Pizzardi Hospital in Bologna, Italy, which keeps the rights on donors’ blood samples. This authorization is available to the Editor.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures



Similar articles
-
Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage.Oncotarget. 2017 Apr 17;8(33):54506-54517. doi: 10.18632/oncotarget.17138. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903359 Free PMC article.
-
Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.Adv Clin Exp Med. 2014 Nov-Dec;23(6):877-84. doi: 10.17219/acem/37330. Adv Clin Exp Med. 2014. PMID: 25618112
-
Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette-Guérin Immunotherapy of Bladder Cancer.Cells. 2024 Apr 18;13(8):699. doi: 10.3390/cells13080699. Cells. 2024. PMID: 38667314 Free PMC article. Review.
-
Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.Mol Med Rep. 2020 Jul;22(1):362-370. doi: 10.3892/mmr.2020.11090. Epub 2020 Apr 22. Mol Med Rep. 2020. PMID: 32319653 Free PMC article.
-
Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.APMIS. 2020 Feb;128(2):92-103. doi: 10.1111/apm.13011. Epub 2020 Jan 28. APMIS. 2020. PMID: 31755155 Review.
Cited by
-
State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.Biosensors (Basel). 2022 Sep 27;12(10):796. doi: 10.3390/bios12100796. Biosensors (Basel). 2022. PMID: 36290934 Free PMC article. Review.
-
Altered Glycosylation in Progression and Management of Bladder Cancer.Molecules. 2023 Apr 13;28(8):3436. doi: 10.3390/molecules28083436. Molecules. 2023. PMID: 37110670 Free PMC article. Review.
-
Progress on liposome delivery systems in the treatment of bladder cancer.RSC Adv. 2025 May 6;15(18):14315-14336. doi: 10.1039/d5ra00746a. eCollection 2025 Apr 28. RSC Adv. 2025. PMID: 40330044 Free PMC article. Review.
-
Immune Predictors of Response after Bacillus Calmette-Guérin Treatment in Non-Muscle-Invasive Bladder Cancer.Cancers (Basel). 2023 Nov 23;15(23):5554. doi: 10.3390/cancers15235554. Cancers (Basel). 2023. PMID: 38067259 Free PMC article. Review.
-
High Expression of the Sda Synthase B4GALNT2 Associates with Good Prognosis and Attenuates Stemness in Colon Cancer.Cells. 2020 Apr 11;9(4):948. doi: 10.3390/cells9040948. Cells. 2020. PMID: 32290493 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical